Skip to main content
. Author manuscript; available in PMC: 2014 Jul 10.
Published in final edited form as: J Control Release. 2013 Apr 6;169(0):17–27. doi: 10.1016/j.jconrel.2013.03.033

Fig. 1. 4-(N)-GemC18-SLNs down-regulate RRM1 expression and increase dFdCTP level in the RRM1-overexpressing TC-1-GR cells.

Fig. 1

(A) The IC50 values of gemcitabine HCl, 4-(N)-GemC18 in DMSO, 4-(N)-GemC18 mixed with blank SLNs, and the 4-(N)-GemC18-SLNs in TC-1 and TC-1-GR cells (n ≥ 3). aP < 0.05. (B) Representative western blot of RRM1 protein levels in TC-1-GR cells after treatment with 4 μM of gemcitabine HCl or the molar equivalent concentration of 4-(N)-GemC18 in DMSO (GemC18), or 4-(N)-GemC18-SLNs for 48 h (n ≥ 3). (C) The intrinsic levels of dCTP and dATP in TC-1 and TC-1-GR cells (n = 3). bP < 0.001, cP < 0.01, TC-1 vs. TC-1-GR. (D) dCTP level in TC-1-GR cells 24 h after treatment with 10 μM of gemcitabine HCl, 4-(N)-GemC18 alone, or 4-(N)-GemC18-SLNs (n = 3). dP < 0.05 vs. PBS. (E) dFdCTP levels in TC-1 and TC-1-GR cells after 24 h of incubation with gemcitabine HCl (10 μM) (n = 3). eP < 0.01. (F) dFdCTP level in TC-1-GR cells after 24 h of incubation with 10 μM of gemcitabine HCl, 4-(N)-GemC18 alone, or 4-(N)-GemC18-SLNs (n = 3). gP < 0.01; fP < 0.001 vs. gemcitabine.

HHS Vulnerability Disclosure